Nina Webster
Follow
Get notifications in MyBN when activity occurs.
Nina Webster
Chief Executive, Managing Director / Dimerix
Most Notable Role
Dr Nina Webster has more than 12 years of senior executive experience, including leading investor relations and business development activities in biotech companies, in a career that spans over 25 years globally in the pharmaceutical and biotechnology industry.
She began her career in new product development with Wyeth Pharmaceuticals (now part of Pfizer) in the UK before moving to Australia. Dr Webster was the commercial director of Acrux where she was responsible for the strategic identification, development and maintenance of commercial partnerships globally, the intellectual property portfolio and investor relations. She also had a lead role in multiple commercial transactions with global pharmaceutical companies that collectively netted over $300 million in revenue to date, and she prosecuted several complex US-based intellectual property matters. Prior to that, she was the director of commercialisation & IP for Immuron.
Dr Webster holds a PhD in Pharmaceutics (Drug Delivery) from Cardiff University, a Bachelors degree in Pharmacology, a Master in Intellectual Property Law from Melbourne University, and an MBA from RMIT.
She began her career in new product development with Wyeth Pharmaceuticals (now part of Pfizer) in the UK before moving to Australia. Dr Webster was the commercial director of Acrux where she was responsible for the strategic identification, development and maintenance of commercial partnerships globally, the intellectual property portfolio and investor relations. She also had a lead role in multiple commercial transactions with global pharmaceutical companies that collectively netted over $300 million in revenue to date, and she prosecuted several complex US-based intellectual property matters. Prior to that, she was the director of commercialisation & IP for Immuron.
Dr Webster holds a PhD in Pharmaceutics (Drug Delivery) from Cardiff University, a Bachelors degree in Pharmacology, a Master in Intellectual Property Law from Melbourne University, and an MBA from RMIT.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 85th | Dimerix | 103% | 22% |
| 1142nd | Limeade Inc | -28% | -44% |
| 1183rd | Latrobe Magnesium | -31% | 45% |
| 1608th | NSX | -59% | -32% |
| 1676th | Group 6 Metals | -66% | -7% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 803rd |  | Dimerix | $9.0m |
| 945th | | NSX | $2.0m |
| 947th | | Latrobe Magnesium | $1.9m |
| 949th | | Limeade Inc | $1.9m |
| 951st | | Group 6 Metals | $1.8m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Non-Executive Director, Linear Clinical Research | 13 Oct 2023 |
| NEWS: Tagged in Biotech company inks $230m deal | 13 Oct 2023 |
| REMUNERATION UPDATE: Chief Executive, Managing Director, Dimerix | 02 Nov 2020 |
| REMUNERATION UPDATE: Chief Executive, Managing Director, Dimerix | 24 Aug 2020 |
